HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients.

The cardioprotective effect of HDL is thought to be largely determined by its cholesterol efflux capacity, which was shown to inversely correlate with atherosclerotic cardiovascular disease in populations with normal kidney function. Patients with ESRD suffer an exceptionally high cardiovascular risk not fully explained by traditional risk factors. Here, in a post hoc analysis in 1147 patients with type 2 diabetes mellitus on hemodialysis who participated in the German Diabetes Dialysis Study (4D Study), we investigated whether the HDL cholesterol efflux capacity is predictive for cardiovascular risk. Efflux capacity was quantified by incubating human macrophage foam cells with apoB-depleted serum. During a median follow-up of 4.1 years, 423 patients reached the combined primary end point (composite of cardiac death, nonfatal myocardial infarction, and stroke), 410 patients experienced cardiac events, and 561 patients died. Notably, in Cox regression analyses, we found no association of efflux capacity with the combined primary end point (hazard ratio [HR], 0.96; 95% confidence interval [95% CI], 0.88 to 1.06; P=0.42), cardiac events (HR, 0.92; 95% CI, 0.83 to 1.02; P=0.11), or all-cause mortality (HR, 0.96; 95% CI, 0.88 to 1.05; P=0.39). In conclusion, HDL cholesterol efflux capacity is not a prognostic cardiovascular risk marker in this cohort of patients with diabetes on hemodialysis.

[1]  S. Bakker,et al.  HDL Cholesterol Efflux Predicts Graft Failure in Renal Transplant Recipients. , 2016, Journal of the American Society of Nephrology : JASN.

[2]  W. März,et al.  Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[3]  W. März,et al.  HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients. , 2015, Journal of the American Society of Nephrology : JASN.

[4]  A. Khera,et al.  HDL cholesterol efflux capacity and incident cardiovascular events. , 2014, The New England journal of medicine.

[5]  N. Vaziri Risk factors: HDL-cholesterol levels and mortality in patients with ESRD , 2014, Nature Reviews Nephrology.

[6]  K. Kalantar-Zadeh,et al.  Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  Raymond Vanholder,et al.  Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure , 2014, The Lancet.

[8]  W. März,et al.  HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. , 2014, Journal of the American Society of Nephrology : JASN.

[9]  Chih-Cheng Hsu,et al.  Diabetes and End-Stage Renal Disease Synergistically Contribute to Increased Incidence of Cardiovascular Events: A Nationwide Follow-up Study During 1998–2009 , 2013, Diabetes Care.

[10]  R. D'Agostino,et al.  High-density lipoproteins: a consensus statement from the National Lipid Association. , 2013, Journal of clinical lipidology.

[11]  Chi Pang Wen,et al.  Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention , 2013, The Lancet.

[12]  R. Dullaart,et al.  Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research. , 2013, Biomarkers in medicine.

[13]  A. Akhmedov,et al.  Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. , 2013, Immunity.

[14]  J. Kastelein,et al.  Genetics of HDL-C: A Causal Link to Atherosclerosis? , 2013, Current Atherosclerosis Reports.

[15]  M. Woodward,et al.  Prediction of kidney-related outcomes in patients with type 2 diabetes. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  J. Heinecke,et al.  The not-so-simple HDL story: A new era for quantifying HDL and cardiovascular risk? , 2012, Nature Medicine.

[17]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[18]  T. Kassimatis,et al.  Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era. , 2012, Journal of nephrology.

[19]  W. Hörl,et al.  Serum amyloid A in uremic HDL promotes inflammation. , 2012, Journal of the American Society of Nephrology : JASN.

[20]  W. Annema,et al.  Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies , 2012, Nutrition & Metabolism.

[21]  A. Hofman,et al.  Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy , 2012, Heart.

[22]  R. Birner-Gruenberger,et al.  Uremia alters HDL composition and function. , 2011, Journal of the American Society of Nephrology : JASN.

[23]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[24]  A. Khera,et al.  Future Therapeutic Directions in Reverse Cholesterol Transport , 2010, Current atherosclerosis reports.

[25]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[26]  Keith C. Norris,et al.  Reverse Cholesterol Transport Pathway in Experimental Chronic Renal Failure , 2009, American Journal of Nephrology.

[27]  G. Norata,et al.  Modified HDL: biological and physiopathological consequences. , 2006, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[28]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[29]  N. Vaziri,et al.  Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure. , 2002, American journal of physiology. Endocrinology and metabolism.

[30]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.